AI: DeepSeek (deepseek-chat)

Q: {
  "prompt": "Please analyze the clinical note against the provided guideline and suggest improvements to better align with the guideline recommendations.\n\nFor each recommendation, specify:\n1. The type of recommendation:\n   - Additional information needed (history/examination/investigations)\n   - Improved patient advice (options/statistics/patient information)\n   - Different management plan\n2. The specific recommendation\n3. The reason for the recommendation (referencing the guideline)\n\nCategorize each recommendation by importance:\n- Very Important: Critical for patient safety or guideline compliance\n- Somewhat Important: Significant for optimal care but not critical\n- Less Important: Would improve care but not essential\n- Unimportant: Minor suggestions that could be considered\n\nFormat the response as follows:\n\n### Very Important Recommendations\n[Type] - [Specific recommendation]\nReason: [Reference to guideline ID and relevant section]\n\n### Somewhat Important Recommendations\n[Type] - [Specific recommendation]\nReason: [Reference to guideline ID and relevant section]\n\n### Less Important Recommendations\n[Type] - [Specific recommendation]\nReason: [Reference to guideline ID and relevant section]\n\n### Unimportant Recommendations\n[Type] - [Specific recommendation]\nReason: [Reference to guideline ID and relevant section]\n\nClinical Note:\nDictation: Clinical Interaction – Twin Pregnancy with Obstetric Cholestasis\n Patient Details:\nName: [Fictional Name] Sarah Ahmed\n\n\nAge: 32\n\n\nBMI: 24.7 (weight 68 kg, height 1.66 m)\n\n\nGravida: 2, Para: 1 (previous spontaneous vaginal delivery at term)\n\n\nCurrent Gestation: 32+2 weeks (DCDA twins confirmed on early scan)\n\n\nBooking bloods and anomaly scans: Unremarkable\n\n\nHistory of Presenting Complaint:\n Ms. Ahmed presents with a 10-day history of worsening pruritus, predominantly affecting her palms and soles, with associated sleep disturbance. She denies any new skin rashes or recent medication changes. No history of abdominal pain, dark urine, or pale stools. Fetal movements are reported as normal for both twins. No vaginal bleeding or uterine tightenings.\nRelevant Obstetric History:\nPrevious pregnancy uncomplicated; term vaginal delivery.\n\n\nNo history of intrahepatic cholestasis in prior pregnancy.\n\n\nNo history of preterm labour or hypertensive disorders.\n\n\nRelevant Medical History:\nMild childhood asthma (not on regular treatment).\n\n\nNo known liver or gallbladder disease.\n\n\nMedications & Allergies:\nCurrently taking ferrous fumarate and pregnancy multivitamin.\n\n\nNo known drug allergies.\n\n\nSocial History:\nLives with husband and toddler son.\n\n\nNon-smoker; does not consume alcohol.\n\n\nWorks part-time as a dental nurse; currently on maternity leave.\n\n\nExamination Findings:\nGeneral: Alert and well, no jaundice noted.\n\n\nAbdomen: Uterus consistent with gestational age; fundal height 33 cm.\n\n\nTwins in cephalic/cephalic lie; both heartbeats auscultated and regular.\n\n\nNo uterine tenderness or signs of labour.\n\n\nNo peripheral oedema; BP 118/74 mmHg.\n\n\nNotable Omissions (for testing purposes):\nNo documented baseline bile acid levels from booking bloods.\n\n\nNo record of fetal growth scan within the last 2 weeks.\n\n\nNo documentation of CTG to assess current fetal wellbeing.\n\n\nImpression:\n Twin pregnancy (DCDA) complicated by suspected obstetric cholestasis. Pruritus in the absence of rash raises concern for intrahepatic cholestasis of pregnancy (ICP), particularly given gestation and multifetal pregnancy.\nManagement Plan:\nInvestigations:\n\n\nSerum bile acids and liver function tests (LFTs) urgently.\n\n\nFasting bile acids if initial results are borderline.\n\n\nFull blood count and clotting screen (due to potential risk of coagulopathy).\n\n\nCTG to assess fetal wellbeing.\n\n\nGrowth scan and umbilical artery Dopplers if not done in past 2 weeks.\n\n\nMedical Management:\n\n\nStart ursodeoxycholic acid 500 mg BID while awaiting results.\n\n\nConsider chlorphenamine for symptomatic relief of itching.\n\n\nOngoing Care and Delivery Planning:\n\n\nWeekly bile acids and LFTs.\n\n\nIncrease surveillance: twice-weekly CTGs and weekly growth scans.\n\n\nAim for delivery at 36–37 weeks if bile acids <100 µmol/L.\n\n\nConsider earlier delivery if bile acids ≥100 µmol/L or evidence of fetal compromise.\n\n\nCounseling Provided:\n\n\nDiscussed nature of obstetric cholestasis and increased risk of stillbirth in twin pregnancies.\n\n\nReassured about ongoing monitoring and early delivery plan.\n\n\nAdvised to monitor fetal movements closely and report any reduction.\n\n\nProvided written information and contact details for triage if symptoms worsen.\n\n\nDictated by: Dr. [Fictional Name] Patel\n Date: [Fictional Date]\n--Note: This is a fictional dictation for testing purposes only. No real patient data or medical advice is contained herein.\n\n\n\nGuideline:\n[ID] bashh-2014-mx-of-vulval-conditions-pdf\nTitle: BASHH - 2014 - Mx of Vulval Conditions.pdf\nContent:  2014 UK National Guideline on the Management of Vulval Conditions\n\nNew in the 2014 Guidelines:\n- General advice for the management of vulval disorders\n- Onward referral guidelines\n- Vulval lichen simplex\n- Vulval psoriasis\n- Use of calcineurin inhibitors\n\nObjectives:\n- Recommendations on the management of vulval disorders\n- Concentrates on a select group of conditions\n- Offers guidance for onward referral\n\nGeneral Advice for all vulval conditions:\n- Avoid irritants\n- Inform GP\n- Consider STI screening\n- Assess for sexual dysfunction\n\nVulval lichen sclerosus:\n- Symptoms include itch, soreness, dyspareunia\n- Signs include pale, white areas, fissuring, erosions\n- Complications may include squamous cell carcinoma\n- Diagnosis through clinical appearance and histology\n- Treatment with ultra-potent topical steroids\n\nVulval lichen planus:\n- Symptoms include itch, soreness, dyspareunia\n- Signs include different lesions types\n- Complications may include scarring and carcinoma\n- Diagnosis through clinical appearance and histology\n- Treatment with biopsy and topical steroids\n\nSmall risk of neoplastic change. Recommended Regimen: Ultrapotent topical steroids like Clobetasol proprionate. Maintenance treatment may be required with weaker steroid preparations. Vaginal corticosteroids may be used in more severe cases. Alternative regimens may include ultra-potent topical steroids with antibacterial and antifungal properties. Topical steroids are safe to use during pregnancy or breastfeeding. Referral to a vulval clinic is recommended for erosive disease or recalcitrant cases. Follow-up at 2-3 months is advised. Biopsy should be performed in non-responsive cases. \n\nVulval eczema: Avoidance of precipitating factors is recommended. Use of emollient soap substitute and topical corticosteroids are advised. Follow-up as clinically required. \n\nLichen simplex: Avoidance of precipitating factors and use of emollient soap substitute are recommended. Topical corticosteroids and anxiolytic antihistamines may be used. Cognitive behavioral therapy may be helpful. Follow-up as clinically required. \n\nVulval psoriasis: Avoidance of irritating factors and use of emollient soap substitute are recommended. Topical corticosteroids and coal-tar preparations may be used. Follow-up as clinically required. \n\nVulval intraepithelial neoplasia (VIN): Referral for colposcopy is recommended. Treatment options include local excision, imiquimod cream, or vulvectomy. Follow-up is mandatory. \n\nVulval pain: Vulvodynia is defined as vulvar discomfort without visible findings. Treatment depends on the type of vulvodynia.\n\nAetiology: Likely multifactorial, with a history of recurrent vulvovaginal candidiasis as a common feature.\n\nClinical Features: Vulval pain, focal tenderness, no signs of acute inflammation.\n\nComplications: Sexual dysfunction, psychological morbidity.\n\nDiagnosis: Clinical diagnosis based on history and examination.\n\nManagement: Exclude other treatable causes before further investigation. Multidisciplinary approach to patient care recommended.\n\nTreatment: Avoid irritating factors, use emollient soap substitute, consider topical local anaesthetics with caution. Physical therapies, cognitive behaviour therapy, pain modifiers, and surgery may be options.\n\nFollow-up: As clinically required, long-term follow-up and psychological support may be necessary.\n\nUnprovoked Vulvodynia: Aetiology unknown, managed as a chronic pain syndrome.\n\nClinical Features: Longstanding unexplained pain, may be associated with urinary symptoms.\n\nComplications: Sexual dysfunction, psychological morbidity.\n\nDiagnosis: Clinical diagnosis after excluding other causes.\n\nManagement: Exclude other treatable causes before further investigation. Multidisciplinary approach to patient care recommended.\n\nTreatment: Use emollient soap substitute, consider pain modifiers like tricyclic antidepressants. Referral to a pain clinic may be necessary for treatment-resistant cases.\n\nFollow-up: As clinically required.\n\nGuidelines for the management of Vulvodynia. Long-term results of therapeutic approach to provoked vestibulodynia. Pelvic floor muscle assessment outcomes in women with and without provoked vestibulodynia. Transcutaneous electrical nerve stimulation to treat vestibulodynia. Use of Amielle Vaginal Trainers in the treatment of Vestibulodynia. Psychological predictors of treatment outcome for provoked vestibulodynia. Long-term follow up of posterior vestibulectomy for treating vulvar vestibulitis. Treatment of vulvodynia with tricyclic antidepressants. Evaluation of gabapentin in the treatment of generalized vulvodynia. Pregabalin-induced remission in a woman with vulvodynia. A randomized clinical trial for women with vulvodynia: Cognitive-behavioral therapy vs. supportive psychotherapy. Acupuncture for vulvodynia.",
  "system_prompt": "You are a medical guidelines compliance checker. Your task is to analyze if the given clinical note follows the specified guideline and suggest improvements.",
  "guideline_id": "bashh-2014-mx-of-vulval-conditions-pdf",
  "guideline_title": "BASHH - 2014 - Mx of Vulval Conditions.pdf"
}

A: Based on the provided clinical note and guideline, there appears to be a significant mismatch between the patient's condition (twin pregnancy with obstetric cholestasis) and the guideline's focus (management of vulval conditions). The guideline does not address obstetric cholestasis or twin pregnancy management. 

### Very Important Recommendations
[Different management plan] - Disregard this guideline for this patient's condition and instead consult guidelines for obstetric cholestasis and twin pregnancy management.
Reason: The provided BASHH guideline is entirely irrelevant for managing obstetric cholestasis in twin pregnancy. This is critical for patient safety as following incorrect guidelines could lead to inappropriate management.

### Somewhat Important Recommendations
[Additional information needed] - Document whether vulval examination was performed given the patient's pruritus.
Reason: While not the primary concern, the guideline recommends assessing for vulval conditions in patients with genital symptoms (General Advice section). However, this is secondary to the obstetric cholestasis management.

### Less Important Recommendations
[Improved patient advice] - Consider adding advice about vulval care if pruritus extends to genital area.
Reason: The guideline recommends general vulval care advice (avoid irritants, use emollients) which could be marginally relevant if symptoms involve the vulva. However, this is not essential given the primary diagnosis.

### Unimportant Recommendations
None applicable given the complete mismatch between the clinical scenario and guideline.

Note: The clinician should instead consult:
1. RCOG Green-top Guideline No. 43 (Obstetric Cholestasis)
2. Twin pregnancy management guidelines
3. Local obstetric protocols for multifetal pregnancies

The current management plan in the note appears appropriate for obstetric cholestasis in twins, aside from the irrelevant guideline reference. The omissions noted in the "testing purposes" section would indeed be important to address in actual practice.

--- Token Usage Report ---
Prompt tokens: 2026
Completion tokens: 375
Total tokens: 2401
Estimated cost: $0.001200